Stock CABA CABALETTA BIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Cabaletta Bio, Inc.

Equities

CABA

US12674W1099

Market Closed - Nasdaq
Other stock markets
 21:00:02 16/05/2024 BST 		5-day change 1st Jan Change
12.62 USD -0.59% Intraday chart for Cabaletta Bio, Inc. +4.43% -44.43%
05-15 Cabaletta Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
03-22 HC Wainwright Adjusts Cabaletta Bio's Price Target to $30 From $25, Maintains Buy Rating MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Cabaletta Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Cabaletta Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Cabaletta Bio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Cabaletta Bio Gets Orphan Drug Designation From FDA For Systemic Sclerosis Treatment
Cabaletta Bio Secures Orphan Drug Designation for Myositis Treatment
Cabaletta, Inc. Announces FDA Grants Orphan Drug Designation to CABA-201
Cabaletta Bio Gets Additional FDA Fast Track Labels For CABA-201
Cabaletta Bio, Inc. Receives Additional FDA Fast Track Designations for CABA-201 in Dermatomyositis and Systemic Sclerosis
Sector Update: Health Care Stocks Retreat in Late Afternoon
Sector Update: Health Care
FDA Probes T-Cell Malignancies in Patients Receiving CAR-T Cell Therapies
Cabaletta Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Cabaletta Bio Says US FDA Cleared Generalized Myasthenia Gravis Phase 1/2 Study of CABA-201
Cellares and Cabaletta Bio, Inc. Partner to Evaluate Automated Manufacturing for CABA-201
Cabaletta Bio, Inc. Receives FDA Clearance of CABA-201 IND Application for Treatment of Generalized Myasthenia Gravis
Cabaletta Bio Insider Sold Shares Worth $146,921, According to a Recent SEC Filing
Cabaletta Bio Gets FDA Clearance For Trial in Systemic Sclerosis
Cabaletta Bio, Inc. Receives U.S. Food and Drug Administration Clearance of Investigational New Drug Application for Treatment of Systemic Sclerosis with CABA-201
Top Midday Gainers
Insider Sell: Cabaletta Bio
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CABA Stock
  4. News Cabaletta Bio, Inc.
  5. Other languages